Gastroenterology
Promising therapies available for the treatment of Crohn disease
Published in Gene Therapy Weekly, June 24th, 2004
"Therapy for Crohn's disease (CD) is rapidly evolving with the emergence of new discoveries in disease pathogenesis. Since the approval of the first biological agent, infliximab, there have been several others that have been studied and are available for use within the context of clinical trials, in CD patients who do not respond to conventional medications or whose disease cannot be maintained in remission with the use of infliximab," scientists at the University of Pennsylvania report.
"The number of available drugs that have focused on the inhibition of TNF is growing. To avoid...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-06-24)
More Articles from Gene Therapy Weekly
- Gene Induction
Inducible promoters aid gene expression in head and neck cancer cells - Gene Transfer
High-capacity hybrid viral vectors garner transduction stability - Genetic Engineering
Stem cell factor gene-modified natural killer cells overwhelm tumor cells - Metastasis
Antisense oligonucleotides diminish breast cancer cell migration - Tumor Suppression
Adenoviruses bearing gfp-zeocin fusion cassettes select p53-deficient cells - Bioengineering
2'-O-methyl- groups stabilize the binding of phosphorothioate antisense ODNs - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
